Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California. Show more

Location: 60 Leveroni Court, Novato, CA, 94949, United States | Website: https://www.ultragenyx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

3.428B

52 Wk Range

$29.59 - $60.37

Previous Close

$36.26

Open

$36.57

Volume

1,815,186

Day Range

$36.48 - $39.87

Enterprise Value

3.834B

Cash

494.4M

Avg Qtr Burn

-97.48M

Insider Ownership

3.20%

Institutional Own.

98.45%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
UX111 (ABO-102) Details
Rare diseases, Sanfilippo Syndrome

PDUFA

Approval decision

DTX401 Details
Glycogen Storage Disease Type Ia

BLA

Submission

DTX301 Details
Ornithine transcarbmylase deficiency

Phase 3

Data readout

GTX-102 Details
Angelman Syndrome

Phase 3

Data readout

UX143 (Setrusumab) Details
Osteogenesis imperfecta

Phase 2/3

Update

UX701 Details
Rare diseases, Wilson's disease

Phase 1/2

Data readout

UX053 Details
Rare diseases, glycogen storage disease type III

Phase 1/2

Data readout